Pharmacokinetics of alectinib and its metabolite M4 in a patient with advanced lung adenocarcinoma undergoing hemodialysis: A case report

Abstract This study presents the first detailed pharmacokinetic data of alectinib and its metabolite M4 in a patient with anaplastic lymphoma kinase (ALK)‐rearranged lung adenocarcinoma undergoing hemodialysis. When the patient was administered a daily 300 mg bid dose of alectinib, the maximal obser...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Ji Eun Park, Young‐Ran Yoon, Chang Ho Kim, Jaehee Lee
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Wiley 2022-04-01
Sarja:Thoracic Cancer
Aiheet:
alectinib
ALK rearrangement
lung cancer
M4
pharmacokinetics
Linkit:https://doi.org/10.1111/1759-7714.14357
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia